America is about to hit a 'vaccine wall' as demand drops — with or without Johnson & Johnson
When U.S. officials temporarily paused the use of Johnson & Johnson’s COVID-19 vaccine Tuesday to warn patients and providers of an “extremely rare” blood clotting issue that has so far affected just six of the millions of Americans who have received the vaccine — all six of them women ages 18 to 48 — many observers the abrupt move would stop a substantial number of Americans from getting vaccinated. But if you take a closer look at the data, it’s clear that unless regulators end up pulling J&J from the market — an outcome experts have all ...
Click
To Read Full Article